search
Back to results

Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot

Primary Purpose

Diabetic Foot

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
V.A.C. ® System
Sponsored by
3M
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Foot focused on measuring Wound closure, Foot salvage, Accelerated healing, Amputation Wounds of the Diabetic Foot

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Presence of a diabetic foot amputation wound up to the transmetatarsal region of the foot Evidence of adequate perfusion by one of the following on the affected extremity, (within the past 60 days): Dorsum transcutaneous oxygen test (TcPO2) with results of ≥30 mmHg, or Ankle brachial index (ABIs) with results of ≥0.7 and ≤1.2 and toe pressures with results of ≥30 mmHg, or Doppler arterial waveforms, which are triphasic or biphasic at the ankle in the affected leg. Age ≥ 18 years of age HbA1c ≤ 12% (collected within the last 90 days.) Evidence of adequate nutrition by one of the following: Lab results reflecting Pre-Albumin ≥16 mg/dl and Albumin level is ≥3 g/dl (during the seven days prior to the study period), or A nutritional consult will be done and with appropriate supplementation started. Proper documentation on (case report forms)CRFs is needed. Exclusion Criteria: Patients with recognized active Charcot abnormalities of the foot, as evidence by clinical symptoms that interfere with either randomized treatment group Wounds resulting from electrical, chemical, or radiation burns, or venous insufficiency Untreated infection or cellulitis at site of target wound Presence of untreated osteomyelitis Collagen vascular disease Malignancy in the wound Presence of necrotic tissue in the wound Uncontrolled hyperglycemia Concomitant medications that include (washout period of 30 days for corticosteroids, immunosuppressive medications, or chemotherapy) Prior V.A.C.® therapy within 30 days. Current or prior normothermic (Warm-UP®) or hyperbaric oxygen (HBO) therapy within 30 days. Current or prior treatment with recombinant or autologous growth factor products within the past 30 days. (Examples: Regranex or Procuren) Current or prior treatment with skin or dermal substitutes and dressings (Examples: Apligraf, Dermagraft, or Integra) with living cells capable of producing growth factors (Example: Oasis) within the past 30 days.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    To determine the effect of V.A.C. ® Therapy on the incidence of complete wound closure.

    Secondary Outcome Measures

    To determine the effect of V.A.C. ® Therapy on the accelerated wound closure or facilitation of surgical closure
    To determine the incidence of foot salvage, as defined by retention of transmetatarsal amputation with no further revisions at end of study
    To determine the change in wound area over time
    To determine the incidence of complications
    To determine the effect of V.A.C. ® Therapy on the quality of life

    Full Information

    First Posted
    September 21, 2005
    Last Updated
    July 29, 2022
    Sponsor
    3M
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00224796
    Brief Title
    Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot
    Official Title
    A Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure® Therapy in the Treatment and Blinded Evaluation of Amputation Wounds of the Diabetic Foot
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2022
    Overall Recruitment Status
    Completed
    Study Start Date
    May 2002 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    October 2005 (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    3M

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this study is to compare the effectiveness of Vacuum Assisted Closure® (V.A.C.®) Therapy to moist wound therapy of amputation wounds of the diabetic foot. The primary objective is to determine the effect of V.A.C.® Therapy on the incidence of complete wound closure. Secondary objectives include evaluating the acceleration of wound closure, facilitation of surgical closure, incidence of foot salvage, and incidence of wound complications.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetic Foot
    Keywords
    Wound closure, Foot salvage, Accelerated healing, Amputation Wounds of the Diabetic Foot

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    146 (false)

    8. Arms, Groups, and Interventions

    Intervention Type
    Device
    Intervention Name(s)
    V.A.C. ® System
    Primary Outcome Measure Information:
    Title
    To determine the effect of V.A.C. ® Therapy on the incidence of complete wound closure.
    Secondary Outcome Measure Information:
    Title
    To determine the effect of V.A.C. ® Therapy on the accelerated wound closure or facilitation of surgical closure
    Title
    To determine the incidence of foot salvage, as defined by retention of transmetatarsal amputation with no further revisions at end of study
    Title
    To determine the change in wound area over time
    Title
    To determine the incidence of complications
    Title
    To determine the effect of V.A.C. ® Therapy on the quality of life

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Presence of a diabetic foot amputation wound up to the transmetatarsal region of the foot Evidence of adequate perfusion by one of the following on the affected extremity, (within the past 60 days): Dorsum transcutaneous oxygen test (TcPO2) with results of ≥30 mmHg, or Ankle brachial index (ABIs) with results of ≥0.7 and ≤1.2 and toe pressures with results of ≥30 mmHg, or Doppler arterial waveforms, which are triphasic or biphasic at the ankle in the affected leg. Age ≥ 18 years of age HbA1c ≤ 12% (collected within the last 90 days.) Evidence of adequate nutrition by one of the following: Lab results reflecting Pre-Albumin ≥16 mg/dl and Albumin level is ≥3 g/dl (during the seven days prior to the study period), or A nutritional consult will be done and with appropriate supplementation started. Proper documentation on (case report forms)CRFs is needed. Exclusion Criteria: Patients with recognized active Charcot abnormalities of the foot, as evidence by clinical symptoms that interfere with either randomized treatment group Wounds resulting from electrical, chemical, or radiation burns, or venous insufficiency Untreated infection or cellulitis at site of target wound Presence of untreated osteomyelitis Collagen vascular disease Malignancy in the wound Presence of necrotic tissue in the wound Uncontrolled hyperglycemia Concomitant medications that include (washout period of 30 days for corticosteroids, immunosuppressive medications, or chemotherapy) Prior V.A.C.® therapy within 30 days. Current or prior normothermic (Warm-UP®) or hyperbaric oxygen (HBO) therapy within 30 days. Current or prior treatment with recombinant or autologous growth factor products within the past 30 days. (Examples: Regranex or Procuren) Current or prior treatment with skin or dermal substitutes and dressings (Examples: Apligraf, Dermagraft, or Integra) with living cells capable of producing growth factors (Example: Oasis) within the past 30 days.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    David Armstrong, DPM
    Organizational Affiliation
    Rosalind Franklin University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    9522113
    Citation
    Holzer SE, Camerota A, Martens L, Cuerdon T, Crystal-Peters J, Zagari M. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther. 1998 Jan-Feb;20(1):169-81. doi: 10.1016/s0149-2918(98)80044-1. Erratum In: Clin Ther 1998 Mar-Apr;20(2):373.
    Results Reference
    background
    PubMed Identifier
    9204802
    Citation
    Glover JL, Weingarten MS, Buchbinder DS, Poucher RL, Deitrick GA 3rd, Fylling CP. A 4-year outcome-based retrospective study of wound healing and limb salvage in patients with chronic wounds. Adv Wound Care. 1997 Jan-Feb;10(1):33-8.
    Results Reference
    background
    PubMed Identifier
    2714164
    Citation
    Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA. Lower-extremity amputation in people with diabetes. Epidemiology and prevention. Diabetes Care. 1989 Jan;12(1):24-31. doi: 10.2337/diacare.12.1.24.
    Results Reference
    background
    PubMed Identifier
    9188970
    Citation
    Morykwas MJ, Argenta LC, Shelton-Brown EI, McGuirt W. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation. Ann Plast Surg. 1997 Jun;38(6):553-62. doi: 10.1097/00000637-199706000-00001.
    Results Reference
    background
    PubMed Identifier
    10232203
    Citation
    Banwell PE. Topical negative pressure therapy in wound care. J Wound Care. 1999 Feb;8(2):79-84. doi: 10.12968/jowc.1999.8.2.25844. No abstract available.
    Results Reference
    background
    PubMed Identifier
    9176007
    Citation
    Mullner T, Mrkonjic L, Kwasny O, Vecsei V. The use of negative pressure to promote the healing of tissue defects: a clinical trial using the vacuum sealing technique. Br J Plast Surg. 1997 Apr;50(3):194-9. doi: 10.1016/s0007-1226(97)91369-2.
    Results Reference
    background
    PubMed Identifier
    9866605
    Citation
    Sibbald RG. Venous leg ulcers. Ostomy Wound Manage. 1998 Sep;44(9):52-64; quiz 65-6.
    Results Reference
    background
    PubMed Identifier
    16291063
    Citation
    Armstrong DG, Lavery LA; Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005 Nov 12;366(9498):1704-10. doi: 10.1016/S0140-6736(05)67695-7.
    Results Reference
    result
    PubMed Identifier
    17425550
    Citation
    Armstrong DG, Lavery LA, Boulton AJ. Negative pressure wound therapy via vacuum-assisted closure following partial foot amputation: what is the role of wound chronicity? Int Wound J. 2007 Mar;4(1):79-86. doi: 10.1111/j.1742-481X.2006.00270.x.
    Results Reference
    derived

    Learn more about this trial

    Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot

    We'll reach out to this number within 24 hrs